New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function

Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the execution of an agreement with a leading, internationally recognized European university medical center, alongside a contract with a specialized clinical research organization (CRO), to conduct a human study as part of its verification and validation (V&V) program for its NASARIX™ (PL-14) Allergy Blocker.

The study is designed to evaluate the nasal residence time of the NASARIX™ formulation in human subjects - a key performance parameter that reflects how long the product remains within the nasal cavity following administration. This assessment is intended to support the estimation of the product's potential duration of protective barrier function, an important attribute for real-world use.

Unlike interventional clinical trials primarily focused on safety or efficacy, this investigation is structured as a human performance and characterization study, aimed at generating data on product behavior in vivo. The study forms part of Polyrizon's V&V activities and is expected to support the Company's regulatory strategy, including planned submissions to the U.S. Food and Drug Administration (FDA).

The study, titled "Evaluation of Nasal Residence Time of PL-14 Allergy Blocker," will be conducted in accordance with applicable European regulatory frameworks, including Regulation (EU) 2017/745 (MDR) and Good Clinical Practice (GCP) standards.

The selected university medical center is widely recognized as a leading academic institution in the field of otolaryngology (ENT) and clinical research, with extensive expertise in nasal physiology and advanced imaging methodologies. Its capabilities are expected to enable precise, high-resolution evaluation of the formulation's retention, distribution, and persistence within the nasal cavity under controlled conditions.

The study is planned as a single-site investigation involving healthy participants and will utilize repeated measurements over time following administration of the NASARIX™ formulation. These serial observations - including endoscopic visualization techniques, are designed to provide a detailed temporal profile of product retention within the nasal passages.

In parallel, Polyrizon has engaged an experienced CRO to oversee study operations and regulatory processes. This engagement enables the Company to initiate submissions to the relevant European health authorities and ethics committees for authorization to conduct the study, as required prior to study commencement.